Contrave
$ 49,00 – $ 644,00Price range: $ 49,00 through $ 644,00
Cordarone
$ 40,00 – $ 720,00Price range: $ 40,00 through $ 720,00
Copegus
$ 171,00 – $ 452,00Price range: $ 171,00 through $ 452,00
Copegus is a potent antiviral medication specifically designed to treat chronic hepatitis C virus (HCV) infections. As a nucleoside analogue, it works by interfering with the viral replication process to reduce the amount of the virus in the body. This medication is typically used as part of a combination therapy regimen to enhance the overall effectiveness of the treatment. By lowering the viral load, Copegus helps improve liver health and reduces the risk of long-term complications associated with chronic infection. It is an established therapeutic option for adult patients seeking to manage and overcome the challenges of hepatitis C.
Active substance: ribavirin
SKU:
Copegus
Categories: AntiVirals, Hepatitis
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Copegus belongs to a class of antiviral medications known as synthetic nucleoside analogues. It is prescribed exclusively in combination with other antiviral therapeutics for the treatment of chronic hepatitis C virus infection in adult and pediatric patients. Because ribavirin is ineffective as monotherapy and carries major warnings regarding toxicity, Copegus is available in the United States strictly as a prescription-only (Rx) medication under close medical supervision.
Proper administration requires rigorous monitoring of laboratory parameters, including complete blood counts, prior to initiating therapy and throughout the treatment period. Prescribers tailor dosing schedules based on individual clinical profiles, body weight, and viral characteristics.
Copegus – Information for Patients and Caregivers
| Property | Details |
|---|---|
| Active Ingredient | Ribavirin |
| Therapeutic Class | Antiviral (Nucleoside Analogue) |
| Dosage Form | Oral tablet |
| Route of Administration | Oral |
| Primary Purpose | Treatment of chronic hepatitis C virus infection (in combination regimens) |
| Prescription Status | Prescription only (Rx) |
What it’s used for
Copegus is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients with compensated liver disease. Clinical protocols dictate that Copegus must never be administered as a single agent; it must be prescribed in combination with designated antiviral regimens, such as peginterferon alfa-2a or specified direct-acting antivirals, depending on HCV genotype and individual treatment history. The clinical efficacy of Copegus relies entirely on its co-administration with appropriate companion therapies, which together work to reduce viral load and inhibit hepatic inflammation. Treatment eligibility depends on underlying liver function, patient tolerance, and specific hepatitis C strain characteristics evaluated by a qualified healthcare professional.
How the drug works
The precise antiviral mechanism of Copegus against hepatitis C virus is multifactorial. As a synthetic nucleoside analogue structurally related to guanosine, ribavirin undergoes intracellular phosphorylation by cellular enzymes into its active mono-, di-, and triphosphate metabolites. These active forms interfere with viral RNA synthesis through several proposed pathways: competitive inhibition of cellular inosine monophosphate dehydrogenase (IMPDH), which depletes intracellular guanosine triphosphate (GTP) pools; direct inhibition of viral RNA-dependent RNA polymerase; and induction of lethal mutagenesis within the viral RNA genome. The net outcome is a substantial reduction in viral replication capacity when combined with target-specific antiviral agents.
What happens in the body
Following oral administration, Copegus is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations within 1.5 to 3 hours. Co-administration with a high-fat meal substantially increases systemic exposure (both peak concentration and total area under the curve), which is why consistent dosing with food is clinically indicated. Ribavirin distributes extensively throughout body tissues and accumulates selectively inside red blood cells, which lack the enzyme required to dephosphorylate ribavirin derivatives. The terminal elimination half-life of ribavirin is exceptionally prolonged, ranging from 200 to 300 hours after reaching steady-state conditions, owing to slow redistribution from non-plasma compartments. Renal excretion accounts for the primary route of elimination for active and inactive metabolites.
Dosing schedule
Dosage regimens for Copegus are individualized based on body weight, renal clearance, viral genotype, and co-administered medications. Standard daily doses generally range between 800 mg and 1200 mg, divided into two separate doses taken morning and evening. Tablets should be swallowed whole with food to ensure optimal systemic absorption. Dose adjustments, temporary interruptions, or permanent discontinuation are frequently required if significant laboratory abnormalities occur, particularly marked decreases in hemoglobin levels. Patients must strictly adhere to the exact schedule prescribed by their healthcare provider and should not alter doses or discontinue therapy independently.
Compatibility with other medicines
Copegus exhibits clinically significant interactions with several classes of drugs. Concurrent administration with nucleoside reverse transcriptase inhibitors (NRTIs), such as didanosine or zidovudine, is contraindicated or strongly discouraged due to heightened risks of severe mitochondrial toxicity, fatal lactic acidosis, and pronounced anemia. Co-administration with azathioprine can lead to severe myelosuppression and pancytopenia due to IMPDH enzyme inhibition. Antacids containing aluminum or magnesium may decrease ribavirin absorption and should not be taken simultaneously. A comprehensive review of all current prescription drugs, over-the-counter products, and dietary supplements must be conducted by the prescriber prior to therapy initiation.
Adverse reactions
Treatment with Copegus is associated with a distinctive profile of adverse events. Hemolytic anemia is the primary dose-limiting toxicity of ribavirin; significant declines in hemoglobin typically occur within the first four weeks of therapy. Other common systemic adverse effects reported during combination therapy include generalized fatigue, headache, insomnia, nausea, anorexia, weight loss, severe skin itching (pruritus), hair thinning (alopecia), and elevated bilirubin levels. Neuropsychiatric symptoms such as irritability, mood instability, anxiety, and depression may also arise. Regular monitoring of baseline blood counts and chemistry panels is imperative throughout the duration of treatment to detect toxicities early.
Important precautions
Copegus carries major boxed warnings regarding embryo-fetal toxicity and hemolytic anemia. Ribavirin causes severe birth defects and fetal death; therefore, Copegus is strictly contraindicated in pregnant women and in male partners of pregnant women. Extreme caution is required: female patients of childbearing potential and male partners of such females must utilize two effective forms of contraception during therapy and for at least six months following treatment cessation. Monthly pregnancy testing is required throughout this period. In addition, patients with pre-existing cardiac disease must be monitored continuously, as rapid drops in hemoglobin associated with ribavirin can precipitate myocardial ischemia or angina.
Pregnancy, breastfeeding, and other groups
The safety of Copegus during breastfeeding has not been established; due to potential adverse effects in nursing infants, a decision must be made whether to discontinue nursing or stop treatment, taking into account the importance of the drug to the mother. In pediatric populations, Copegus use is restricted to specific approved age groups and combination regimens, with dose calculated based on body surface area or body weight. In elderly patients, dosing should be selected cautiously, reflecting the higher prevalence of decreased renal, hepatic, or cardiac function. Patients with significant renal impairment (creatinine clearance less than 50 mL/min) should not receive Copegus due to the high risk of drug accumulation.
Red flags
Patients receiving Copegus must seek emergency medical intervention if they experience signs of severe acute anemia or cardiovascular distress, such as sudden shortness of breath, severe chest pain, rapid or irregular heartbeat, or extreme dizziness. Immediate care is also required if symptoms of severe hypersensitivity develop, including facial, lip, or tongue swelling, skin rash with blistering, or difficulty swallowing. Signs of severe hepatic decompensation or severe psychiatric distress–including suicidal thoughts or deep clinical depression–warrant urgent medical evaluation.
If you skip a dose
If a dose of Copegus is missed, it should be taken as soon as remembered on the same day, provided it is taken with food. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Under no circumstances should double doses be taken to compensate for a missed dose. Patients experiencing frequent missed doses should consult their provider to maintain therapeutic levels and prevent antiviral treatment failure.
Storage and expiration
Copegus tablets should be stored at controlled room temperature, between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). The container must be kept tightly closed to protect the medication from excessive moisture and heat. Do not use Copegus after the expiration date printed on the bottle label. Keep all medications out of the reach and sight of children and pets.
Common questions
Why must Copegus always be taken with food?
Food substantially increases the bioavailability and total absorption of ribavirin in the digestive tract. Taking Copegus with meals helps achieve optimal therapeutic blood concentrations while minimizing stomach upset.
How often are blood tests required during treatment?
Blood tests–specifically complete blood counts to evaluate hemoglobin levels–are typically performed prior to starting, at weeks 2 and 4 of therapy, and regularly thereafter. Prescribers adjust or interrupt dosing based on these objective laboratory values.
What happens if a pregnancy occurs while taking Copegus?
Treatment must be stopped immediately, and the prescribing physician informed right away. Because ribavirin causes severe birth defects, strict pregnancy prevention using two reliable contraceptive methods is mandatory for both male and female patients during therapy and for six months post-treatment.
Can Copegus be taken alongside alcohol?
Alcohol consumption should be avoided during treatment for hepatitis C. Alcohol accelerates liver fibrosis, impairs liver function, and can aggravate adverse effects associated with combination antiviral therapy.
Is it safe to drive while taking Copegus?
Copegus combination therapy may cause fatigue, dizziness, and somnolence in some individuals. Patients should assess their personal reaction to the medication before driving, operating heavy machinery, or performing tasks requiring alertness.
In accordance with FDA requirements.
Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.
Additional information
| Dosage |
200mg |
|---|---|
| Package |
30 caps ,60 caps ,90 caps |
| Ενεργός Ουσία |
Related products
Acivir Pills
$ 51,00 – $ 200,00Price range: $ 51,00 through $ 200,00
Active substance: Acyclovir
More Details
This product has multiple variants. The options may be chosen on the product page
Amantadine
$ 19,00 – $ 249,00Price range: $ 19,00 through $ 249,00
Active substance: Amantadine
More Details
This product has multiple variants. The options may be chosen on the product page
Capoten
$ 42,00 – $ 323,00Price range: $ 42,00 through $ 323,00
Active substance: Captopril
More Details
This product has multiple variants. The options may be chosen on the product page
Medex
$ 41,00 – $ 144,00Price range: $ 41,00 through $ 144,00
Active substance: Coumadin
More Details
This product has multiple variants. The options may be chosen on the product page
Molnupiravir
$ 229,00 – $ 706,00Price range: $ 229,00 through $ 706,00
Active substance: Molnupiravir
More Details
This product has multiple variants. The options may be chosen on the product page
Movfor
$ 293,00 – $ 1 097,00Price range: $ 293,00 through $ 1 097,00
Active substance: Molnupiravir
More Details
This product has multiple variants. The options may be chosen on the product page
Procardia
$ 28,00 – $ 269,00Price range: $ 28,00 through $ 269,00
Active substance: Nifedipine
More Details
This product has multiple variants. The options may be chosen on the product page
Vermox
$ 45,00 – $ 136,00Price range: $ 45,00 through $ 136,00
Active substance: Mebendazole
More Details
This product has multiple variants. The options may be chosen on the product page
